Cerus Corp (CERS) Stock Price & Analysis
Cerus Corp (CERS) rose 2.09% to USD 2.93 as of July 25, 2026 at 08:10 UTC, according to Nexqual real-time market data.
CERS last closed at USD 2.87; the session ranged USD 2.81–2.94 on volume of 2,455,827 shares. Market capitalization is $587.08M, with a 52-week range of USD 1.15–3.47 (NGM). Source: Nexqual, July 25, 2026 at 08:10 UTC.
Key Statistics (as of July 25, 2026 at 08:10 UTC)
| Price | USD 2.93 |
|---|---|
| Change | ▲ 2.09% (up) |
| Previous Close | USD 2.87 |
| Open | USD 2.87 |
| Day Range | USD 2.81 – 2.94 |
| 52-Week Range | USD 1.15 – 3.47 |
| Volume | 2,455,827 shares |
| Market Cap | $587.08M |
| Exchange | NGM |
Technical Analysis (CERS)
Nexqual's technical model rates CERS "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 08:10 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 46.47 (neutral) |
| vs SMA50 | Above (USD 2.83) |
| MACD | 0.06 (positive) |
Analyst Ratings (CERS)
Wall Street analysts rate CERS "None" based on 3 analysts, with a mean price target of USD 4.67 (range USD 4–5), per Nexqual as of July 25, 2026 at 08:10 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 4.67 |
| High Target | USD 5 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (CERS)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD -0.01 |
| Revenue Estimate | $58.90M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.01 vs est -0.04 ▲ beat |
| 2025-12-31 | USD -0.01 vs est -0.01 ▼ miss |
| 2025-09-30 | USD 0 vs est -0.03 ▲ beat |
| 2025-06-30 | USD -0.03 vs est -0.02 ▼ miss |
Source: Nexqual, July 25, 2026 at 08:10 UTC.
Financials & Fundamentals (CERS)
| Total Revenue | $216.56M |
|---|---|
| Revenue Growth (YoY) | +24.10% |
| Gross Margin | +52.99% |
| Operating Margin | -0.66% |
| Profit Margin | -4.41% |
| ROE | -15.37% |
| Debt / Equity | 142.57 |
| Current Ratio | 1.63 |
| Total Cash | $80.42M |
| Total Debt | $97.36M |
| Free Cash Flow | $2.26M |
Source: Nexqual, July 25, 2026 at 08:10 UTC.
Financial Health Score (CERS)
Nexqual rates Cerus Corp's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 08:10 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 53%, operating -1% |
| Balance Sheet | Mixed — $80M cash vs $97M debt |
| Cash Flow | Mixed — FCF $2M, slim 1.1% margin |
| Efficiency | Critical — ROE -15%, ROA -0.9% |
Ownership (CERS)
| Insider Ownership | +3.69% |
|---|---|
| Institutional Ownership | +73.29% |
| Shares Outstanding | 200.37M |
| Float | 182.94M |
| Short % of Float | +7.04% |
Source: Nexqual, July 25, 2026 at 08:10 UTC.
Leadership (CERS)
Cerus Corp is led by Vivek K. Jayaraman (age 50), CEO, President & Director, per Nexqual as of July 25, 2026 at 08:10 UTC.
| CEO, President & Director | Vivek K. Jayaraman (age 50) |
|---|---|
| Executive Chairman of the Board | William M. Greenman (age 58) |
| VP of Finance & CFO | Kevin D. Green (age 53) |
| Vice President of Global Marketing | Lainie Corten |
Major Backers & Investors (CERS)
Notable institutional backers of Cerus Corp include ARK Invest, Soleus Capital Management, L.P., Baker Bros. Advisors, LP, according to Nexqual as of July 25, 2026 at 08:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 17.46% |
| Soleus Capital Management, L.P. | 5.37% |
| Baker Bros. Advisors, LP | 4.99% |
| WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund | 2.58% |
| Sumitomo Mitsui Trust Group, Inc. | 2.25% |
| Amova Asset Management Americas Inc | 2.25% |
| Silvercrest Asset Management Group, LLC | 2.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 14.47% |
| Vanguard Group | 8.03% |
| Geode Capital | 2.31% |
Source: Nexqual, July 25, 2026 at 08:10 UTC.
From Cerus Corp's Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Cerus Corporation operates as a biomedical products company.
- The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
- The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
- It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CGEN | Compugen Ltd. | USD 2.28 | ▼ 5.79% |
| VCYT | Veracyte, Inc. | USD 56.61 | ▼ 2.41% |
| MCRB | Seres Therapeutics, Inc. | USD 4.97 | ▼ 5.97% |
| BCRX | BioCryst Pharmaceuticals, Inc. | USD 9.34 | ▼ 1.79% |
| CRIS | Curis, Inc. | USD 4.89 | ▼ 1.01% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:10 UTC. This page is informational and not investment advice.